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Immunologic research into pathogenic mechanisms operating in autoimmune-mediated atherosclerosis initially
focused on adaptive immunity. Current interest is directed to more basic inflammatory mechanisms. Chronic
inflammation (innate immunity-associated) may trigger initial events that can lead to atherosclerotic cardiovascular
disease. This chronic inflammation may start early in life and be perpetuated by classic atherosclerosis risk
factors. Lipid peroxidation of low-density lipoprotein seems to be a key event in the initiation and progression of
atherosclerosis. Oxidized low-density lipoprotein triggers inflammatory and immunogenic events that promote
endothelial dysfunction and the synthesis and secretion of pro-inflammatory cytokines, leading to an autoimmune
response capable of accelerating the intracellular accumulation of lipids within atherosclerotic plaques. Oxidized
low-density lipoprotein binds β2-glycoprotein I to form circulating complexes found in both autoimmune and
non-autoimmune atherosclerosis. It is likely that β2-glycoprotein I and/or these complexes contribute to early
atherogenesis by stimulating pro-inflammatory innate immunity through endogenous sensors and inflammasome/
interleukin-1 pathways. We discuss the chronic inflammatory (innate) and autoimmune (adaptive) responses
operating in atherosclerosis to discern the role of autoimmunity in atherosclerotic cardiovascular disease.
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In the last decades, it has become apparent that patients
with systemic autoimmune diseases develop premature
and, quite often, severe atherosclerotic cardiovascular dis-
ease (CVD). Systemic autoimmune diseases are characte-
rized by chronic inflammation and immune dysregulation.
These abnormalities may produce dyslipidemia, platelet
and vascular pathology, arterial lesions, and enhanced
autoantibody production [1-3]. Current narrative for non-
autoimmune atherosclerosis emphasizes the active inflam-
matory, complex or multi-factorial and long-term nature
of the disease. These inflammatory mechanisms also cause
dyslipidemia with vascular and immunologic dysfunction.
Giving the similarities with autoimmune-mediated athero-
sclerosis, it is not surprising that investigators have postu-
lated an autoimmune nature for atherosclerosis.* Correspondence: eijimatu@md.okayama-u.ac.jp
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2014Innate immune mechanisms have been demonstra-
ted in atherosclerosis, particularly in early stages of the
disease. Unraveling the roles of inflammatory molecular
factors and signaling systems activated by a variety of
pathogens and/or endogenous signals highlighted the
prominent role of pro-inflammatory inflammasome/IL-1
cytokines and turned attention to auto-inflammatory
mechanisms in atherosclerosis [4,5]. Whether these pro-
inflammatory mechanisms progress into atherogenic
adaptive immune responses in late stages of the dis-
ease or represent two independent pathologic proces-
ses remains unresolved. Understanding their nature and
inter-relationship in atherosclerosis may provide new con-
cepts with possible impact not only on early and accurate
diagnosis but also on preventive programs and perhaps
more effective therapeutic interventions.Chronic inflammatory mechanisms and immune
dysregulation in atherosclerosis
There is much evidence to suggest that endothelial dys-
function (the primum movens) is an early pro-atherogenical Ltd. This is an Open Access article distributed under the terms of the Creative
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utes to the formation, progression and complications of
atherosclerosis [6]. It is also becoming increasingly clear
that chronic inflammation and immune dysregulation play
important roles in the development of atherosclerotic
CVD, which can now be considered an inflammatory
autoimmune condition [6,7].
Oxidized low-density lipoprotein (oxLDL) is pivotal in
the development of atherosclerosis and represents a cru-
cial pro-inflammatory stimulus [8]. Upon entering into
the intima of arteries, oxLDL activates endothelial cells
and up-regulates adhesion molecule expression and che-
motactic chemokine secretion, all of which contribute to
the recruitment of circulating leukocytes. Monocytes
and/or macrophages infiltrating atherosclerotic sites take
up oxLDL, forming ‘foam cells’ that in turn promote
further secretion of inflammatory mediators. The asso-
ciation between oxLDL autoantibodies and CVD in pa-
tients with rheumatoid arthritis (RA) has been reported
[8]. OxLDL may interact with C-reactive protein (CRP)
to form pro-atherogenic oxLDL/CRP complexes that may
not only perpetuate vascular inflammation but also trigger
autoimmune responses, accelerating the development
of atherosclerosis [9]. OxLDL/β2-glycoprotein I (β2GPI)
complexes also induce adaptive autoimmune responses,
which may up-regulate the macrophage expression of
FcγRI and scavenger CD36 receptors and thus accelerate
oxLDL uptake. OxLDL/β2GPI complexes correlate with
the size of atherosclerotic lesions in mouse models. In pa-
tients with CVD, these complexes correlate with disease
severity and adverse outcomes [5].
Chronic inflammation is a major component of athe-
rogenesis, and both in vitro and in vivo studies have
shown that IL-1β is a potent pro-inflammatory and
atherogenic cytokine [10,11]. The production of IL-1β
depends on two separate signals: the induction of IL-1β
mRNA as a result of the stimulation of pattern recogni-
tion receptors; and the activation of caspase-1, a protease
that cleaves pro-IL-1β into its biologically active form
[12]. The activation of caspase-1 is mediated by cytoplas-
mic large multi-protein complexes, called inflammasomes,
that cleave pro-caspase-1 into its mature activated pro-
teinase form. Caspase-1 is a key bridge linking metabolic
stresses and innate immune sensors to produce pro-
inflammatory cytokines and vascular inflammation [13].
IL-1 is a potent pro-inflammatory cytokine with a wide
range of biological effects. IL-1β can be induced during
infection, metabolic or endogenous injury [14], or im-
munological challenge and can control systemic and local
inflammation by up-regulating the expression of many ef-
fector proteins through the stimulation of IL-1 receptors
and the NF-κB pathway. It also stimulates the synthesis of
IL-6, fibrinogen, CRP and the other inflammatory media-
tors involved in coronary artery syndromes. Furthermore,increased IL-1β mRNA levels in human atherosclerotic
plaques suggests that locally synthesized IL-1 protein may
activate the synthesis of growth factors and other cyto-
kines, leading to local inflammatory cascades [12].
Various studies have shown that Toll-like receptor
(TLR) signaling is operative in the intima of atheroscler-
otic arteries, with a number of pathogens and endogenous
TLR ligands in atherosclerotic lesions. It is therefore con-
ceivable that, together with other pro-atherogenic ligands,
cholesterol crystals can elicit inflammasome/IL-1 inflam-
matory responses [15], a hypothesis supported by the find-
ing that caspase-1 mRNA and caspase protein are present
in atherosclerotic lesions but not in normal arteries.
Cholesterol crystals can induce inflammasome nucleotide-
binding domain leucine-rich repeat receptor protein 3
(NLRP3) activation with IL-1β and IL-18 production. Ac-
tivated caspase-1 has been observed in ruptured but not
stable plaque in patients experiencing sudden coronary
death, and patients with high plasma caspase-1 levels have
significantly lower survival rates after a myocardial in-
farction [13]. As inflammasome-mediated IL-1β release
promotes an inflammatory milieu and drives lesion pro-
gression; cholesterol crystal-induced inflammasome ac-
tivation may be an important link between cholesterol
metabolism and inflammation in atherosclerotic lesions.
Atherosclerosis should therefore be considered an auto-
inflammatory (not autoimmune) disease that triggers the
production of autoantibodies against substances such as
oxLDL [16].
The role of β2GPI in atherogenesis
Dysregulation of inflammatory responses and adaptive
immunity are important pathologic mechanisms under-
lying the clinical manifestations of systemic lupus ery-
thematosus (SLE) and antiphospholipid syndrome. These
patients may develop venous thromboembolism and pre-
mature CVD.
The emerging role of anti-β2GPI and anti-oxLDL anti-
bodies in autoimmune-mediated atherothrombosis was
first recognized in patients with antiphospholipid syn-
drome [17]. The systemic and local generation of free
radicals by inflammatory cells may induce oxidative modi-
fications of LDL. OxLDL generation and uptake by arterial
mononuclear cells activate inflammatory and chemotactic
cytokines in early stages of atherosclerosis, followed by an
excessive oxLDL intracellular accumulation [18]. β2GPI
was initially described as a natural anticoagulant, but
it has more pleiotropic functions affecting fibrinolysis,
angiogenesis, apoptosis and atherogenesis [19]. OxLDL
binds β2GPI via specific oxidized lipid epitopes forming
pro-atherogenic oxLDL/β2GPI complexes [20]. This inter-
action suggests an anti-oxidant role of β2GPI by quen-
ching the pro-inflammatory and pro-atherogenic effects
of oxLDL. OxLDL/β2GPI complexes may also become
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bodies. Current evidence indicates the atherosclerotic
lesion as the primary site for oxLDL/β2GPI complex
formation. Because oxLDL/β2GPI and their immune com-
plexes up-regulate the expression of scavenger and FcγRI
receptors, with rapid accumulation in lysosomes where
danger signals are processed, oxLDL and β2GPI may also
contribute to the activation of inflammasomes [5].
Innate immunity provides a first line of host defense
against a variety of pathogens and endogenous danger
signals. Cells of the innate immune system mediate in-
flammatory responses through signaling receptors to de-
tect pathogens or altered endogenous molecules [21].
These receptors recognize pathogen-associated mole-
cular patterns including damaged tissue and modified
self-molecules [10]. TLRs are extracellular pathogen-
associated molecular pattern sensors capable of trig-
gering signaling cascades that lead to the expression of
pro-inflammatory cytokines, such as tumor necrosis fac-
tor alpha and IL-1 via the NF-κB pathway [22]. There
are two families of intracellular receptors: retinoic acid-
inducible gene I-like helicases and NLRs [23,24]. In
particular, NLRP3 can activate pro-inflammatory caspases
in response to endogenous stimuli. Activated caspase-1
controls the maturation of the pro-inflammatory IL-1
family of cytokines. Inflammasomes are multi-molecular
complexes of NLRP3 that regulate inflammatory cas-
pases and IL-1 production. IL-1β is a potent pro-
inflammatory cytokine with deleterious effects if produced
uncontrollably.
Intracellular NLRP3 can be assembled by lysosomal
damage and reactive oxygen species. Thus, host-derived
oxidation-specific epitopes may activate innate immunity
through a variety of receptors for danger (or damage)-
associated molecular patterns [25]. Lipid peroxidation is
ubiquitous and represents a major component of an ath-
erosclerotic inflammatory state. Endogenous atherogenic
danger signals such as oxLDL and oxLDL/β2GPI may be
capable of dysregulating an inflammasome-induced IL-1β
response, representing an early inflammatory mechanism
in atherogenesis.
High circulating levels of oxLDL/β2GPI may indicate
an advanced endogenous process that is already dissemi-
nated (systemic) and their effects can be detectable by
other means, such as intima media thickness (IMT), an-
giography or imaging. Further, if an antibody response
to any of these elements is present (that is, anti-oxLDL,
anti-β2GPI or anti-oxLDL/β2GPI), the process may have
already reached the level of an adaptive immune re-
sponse causing a full clinical disease expression, possibly
indicating high risk for adverse outcomes. The measure-
ment of these biomarkers may provide specific informa-
tion about an underlying atherogenic inflammasome/
IL-1β response. Intervention (prevention) may be moreeffective at this level as has been shown with classical
auto-inflammatory diseases.
Pro-atherothrombotic milieu in systemic autoimmunity
Nowadays, atherosclerosis is seen as an inflammatory
disease of the arterial vessel [26], and it is therefore not
surprising that the chronic inflammatory disorder RA is
associated with an increased cardiovascular risk. But
autoimmunity also plays a role, because patients with
RA who are rheumatoid negative or anti-cyclic citrulli-
nated peptide negative have less atherosclerotic disease
than patients with RA who have these autoantibodies.
Moreover, SLE is also associated with an increased car-
diovascular risk.
Cells of both the innate and adaptive immune systems
are involved in atherogenesis. The importance of adap-
tive immunity was demonstrated in experimental models
such as apolipoprotein E-deficient mice. T and B cell de-
ficiency reduces the atherosclerotic burden by 40% to
80%, in both early and late phases of atherosclerotic dis-
ease [27,28]. Most T cells in atherosclerotic plaques are
CD4+ and express the αβ-T-cell receptor, which inter-
acts with major histocompatibility complex class II mo-
lecules. T cells infiltrating atherosclerosis lesions have
a Th1 profile that activate macrophages and increases
pro-inflammatory cytokines such as IFN-γ. IFN-γ de-
creases collagen synthesis, making the atherosclerotic fi-
brous cap more vulnerable to rupture or thrombosis.
Th17 lymphocytes represent another T helper subset in-
volved in inflammation but their precise role in athero-
sclerosis is still under investigation. The protective role
of regulatory T cells in atherosclerosis was demonstrated
in patients with acute coronary syndrome who had low
regulatory T cell levels compared with patients with
stable angina and normal coronary arteries [29,30]. A
pro-inflammatory subset of CD4+ T cells lacking the co-
stimulatory receptor CD28 (CD4+, CD28-) is increased
in atherosclerotic plaques from patients with unstable
angina [31,32].
Antiphospholipid and anti-oxLDL antibodies cross-
react and anti-oxLDL/β2GPI complexes are increased
in SLE and RA, providing an initial explanation for
the increased cardiovascular risk in autoimmunity. In
a population-based cohort, the presence of antinuclear
antibodies (ANA) correlated with cardiovascular events
and mortality [33]. The presence of ANA was a significant
independent predictor of cardiovascular events and death,
with hazards ratios of 1.26 and 1.18, respectively. The role
of ANA in preclinical atherosclerosis was investigated in
The Cardiovascular Risk in Young Finns Study [34] of
2,278 participants. ANA positivity was observed in 10.5%
of women and 4.5% of men. Multivariate analyses, ad-
justed for age, body mass index, CRP, lipids, blood pres-
sure and smoking habits, showed that ANA positivity was
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ANA might thus have a role in the development of
early atherosclerosis through induction of endothelial
dysfunction.
TLR signaling by innate immune cells is also import-
ant for the development of atherosclerotic lesions [35].
TLRs are also essential for the adaptive immune system
because they activate dendritic cells and macrophages
with subsequent T and B cell activation. Important en-
dogenous TLR ligands in RA are gp 96 and tenascin C.
The synovial expression of gp 96 increases with in-
flammation, which activates macrophages through TLR2
and TLR4. Inflammation increases the expression of
tenascin-C, activating TLR4. Other TLR ligands include
serum amyloid A, heat shock proteins and high mobility
group box chromosomal protein 1.
Autoimmune disease and atherosclerosis have a num-
ber of pathogenic similarities [36]. Chronic inflammation
underlies both diseases with increased numbers of mac-
rophages, dendritic cells, and B and T lymphocytes. TLR
signaling is also essential in both diseases; however, the
endogenous ligands differ, for example, lipids do not
function as endogenous ligands in RA synovial tissue.
However, gp96, tenascin C or high-mobility group box 1
protein released from the arthritic joint might func-
tion as ligands for macrophages in the atherosclerotic
plaque, with subsequent progression of the lesion. In
SLE, RNA and DNA antibodies can either directly or
indirectly (through plasmacytoid dendritic cells) lead
to increased plaque inflammation and rupture as the
ultimate consequence.
Conclusions
There is increasing evidence that autoimmunity plays an
essential role in atherogenesis. TLR and cytoplasmic
(inflammasome NLRP3) receptors, with their signaling
pathways, are essential components of both the innate
and adaptive immune systems that participate in the
development of autoimmune diseases as well as in athe-
rosclerosis. Systemic autoimmune diseases and atheros-
clerosis share common pathogenic pathways. A chronic
inflammatory background mediated by the TLR and in-
flammasome/IL-1 pathways as seen in auto-inflammatory
diseases and endothelial dysfunction are early steps that
may lead to the development of atherosclerotic plaques.
Several human studies of auto-inflammatory disease have
indicated that this stage may still be reversible. It is temp-
ting to speculate that autoantibodies (an essential com-
ponent of autoimmune diseases) may ultimately cause
structural and irreversible arterial wall damage with subse-
quent atherosclerotic plaque development and rupture.
OxLDL and β2GPI are both inflammatory (innate) and
immunogenic (adaptive) molecules. One possible role for
these molecules is that they may serve as biological linksbridging the progression from chronic inflammation into
a full autoantibody response in later stages of atheroscler-
osis. When autoantibodies are present, patients with RA
have an accelerated atherosclerosis in comparison to pa-
tients with RA who do not have these antibodies. Simi-
larly, autoantibodies in SLE amplify atherosclerosis. Thus,
whether atherosclerosis is an auto-inflammatory disease,
an autoimmune disease, or both is still debatable, with
sound arguments supporting each position.
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